Clinical trials: Stroke/Brain Attack
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203.
- Trial name
- NCT06961344
- Testing
- zagociguat 15mg
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 37 people
- Sponsor
- Tisento Therapeutics
Acute Ischemic Stroke
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).
- Trial name
- NCT07739160
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Tachyarrhythmia, Atrial Fibrillation (AF)
Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk…
- Conditions
- Tachyarrhythmia, Atrial Fibrillation (AF), Syncope, Cryptogenic Stroke
- Trial name
- NCT04025710
- Testing
- BIOMONITOR III and BIOMONITOR IIIm
- Where
- 27 sites in Australia, Austria and 4 more
- Volunteers
- 167 people
- Sponsor
- Biotronik SE & Co. KG
Ischemic Stroke, Acute, Brain Diseases
Safety and Efficacy of SINOMED SR for Endovascular Treatment of Acute Ischemic Stroke
A prospective, multicenter, randomized controlled, non-inferiority study to investigate the effectiveness and safety of SINOMED SR for endovascular treatment of acute ischemic stroke
- Conditions
- Ischemic Stroke, Acute, Brain Diseases, Cerebrovascular Disorders
- Trial name
- NCT04973332
- Testing
- Intracranial thrombectomy stent
- Where
- 14 sites in China
- Volunteers
- 218 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Facial Palsy, Stroke Rehabilitation
Facial Palsy Treatment
The Primary objective of the study is to investigate the most effective treatment modalities available to speech language pathologist as well as movement difference by comparing them.
- Trial name
- NMES (NCT06976814)
- Testing
- Neuro muscular electrical stimulation, Beckmann's oral motor exercises
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Muscle Spasticity, Stroke
Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
- Trial name
- NCT02145689
- Testing
- onabotulinumtoxinA
- Sponsor
- Allergan
Syncope, Cryptogenic Stroke
BIO|STREAM.ICM France
The main objective of the BIO│STREAM.ICM France submodule is to provide clinical evidence from patients in France on safety and efficacy of the BIOMONITOR system
- Trial name
- NCT04206774
- Where
- 3 sites in France
- Volunteers
- 92 people
- Sponsor
- Biotronik SE & Co. KG
Acute Ischemic Stroke
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
- Trial name
- ReMEDy1 (NCT03290560)
- Testing
- Recombinant human tissue kallikrein
- Where
- 12 sites in Australia
- Volunteers
- 92 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Stroke, Cerebral Infarction
ICTUS Study: International Citicoline Trial on Acute Stroke
Citicoline is a safe drug approved in some countries for the treatment of acute ischemic stroke. The drug has shown some evidence of efficacy in a pooled analysis, based on four clinical trials done in USA with oral…
- Trial name
- ICTUS (NCT00331890)
- Testing
- Citicoline
- Where
- 65 sites in Germany, Portugal and 1 more
- Volunteers
- 2,298 people
- Sponsor
- Ferrer Internacional S.A.
Atrial Fibrillation
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT04213807
- Testing
- MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Anthos Therapeutics, Inc.
Homonymous Hemianopsia, Homonymous Quadrantanopia
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery.
- Trial name
- NCT07185971
- Testing
- PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeuroAEye LLC
Spasticity
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of lower limb spasticity, in adults followed by an open-label extension…
- Trial name
- NCT04099667
- Testing
- Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 40 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Stroke
Portable EMG-triggered Hand Robot for Individuals After Stroke
This is an interventional pilot study investigating the feasibility of using the hand of hope (HOH) device for individuals with decreased hand function after stroke.
- Trial name
- NCT02364700
- Testing
- Hand of Hope (HOH)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rehab-Robotics Company Limited
Acute Ischemic Stroke
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1.
- Trial name
- ORION (NCT06990867)
- Testing
- JX10
- Where
- 104 sites in United States, Belgium and 19 more
- Volunteers
- 740 people
- Sponsor
- Corxel Pharmaceuticals
Ischemic Stroke
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
- Trial name
- NCT01958957
- Testing
- Ginkgolides Meglumine Injection
- Where
- 86 sites in China
- Volunteers
- 6,300 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Acute Ischemic Stroke
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to…
- Trial name
- NCT06129175
- Testing
- Neuroncell-EX
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Cytopeutics Sdn. Bhd.
Atrial Fibrillation
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health…
- Trial name
- NCT03572972
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Where
- South Korea
- Volunteers
- 64,684 people
- Sponsor
- Pfizer
Stroke, Acute Ischemic Stroke
Repinotan in Patients With Acute Ischemic Stroke
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
- Trial name
- NCT00044915
- Testing
- Repinotan HCl (BAYX3702)
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 782 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.